Physiomics PLC (GB:PYC)
LSE:PYC
PYC Stock Chart & Stats
0.28 p
0.05 p(6.45%)
At close: 4:00 PM EST
0.28 p
0.05 p(6.45%)
Day’s Range― - ―
52-Week Range0.25 p - 0.80 p
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.43M
Market Cap
£2.06M
Enterprise Value1.27M
Total Cash (Recent Filing)£257.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound In 2025A strong 2025 revenue rebound (≈+51% vs 2024) signals recovering client demand and improving commercial traction. Sustained top-line growth can enable operating leverage, increase repeat-fee opportunities, and support scaling of project teams and multi-phase engagements over the next several quarters.
Debt-free Balance SheetZero reported debt in 2025 provides material financial flexibility during a turnaround. Low leverage lowers refinancing and interest risk, lets management prioritize growth or product investment, and preserves options to raise equity or form partnerships without servicing fixed debt burdens.
Specialized QSP Services And Client BaseA focused fee-for-service QSP and mechanistic modelling offering addresses durable R&D needs of pharma/biotech. Domain expertise creates high switching costs and repeat engagements, enabling steady project pipelines and potential to upsell platform licences or long-term collaborations over time.
Bears Say
Persistent Cash BurnOperating and free cash flow were both materially negative in 2025 and the multi-year pattern shows recurring cash burn. Persistent outflows force reliance on external funding, dilute shareholders, constrain investment in people and tools, and raise execution risk if revenue momentum weakens.
Ongoing Loss-making With Negative MarginsDespite revenue gains, the firm continues to post net losses and deeply negative margins. Chronic inability to convert sales into sustainable profit undermines reinvestment capacity, pressures cash runway, and means management must deliver structural margin improvement to achieve long-term viability.
Negative Returns Eroding Equity CushionA roughly -60% ROE and a modest equity base indicate operating losses are diluting shareholder value. Repeated negative returns risk exhausting the small equity cushion, limiting strategic options and making the company more vulnerable to funding shocks even with no debt on the balance sheet.
Physiomics News
PYC FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest share price was 0.25 p and its highest was 0.80 p in the past 12 months.
What is Physiomics PLC’s market cap?
Physiomics PLC’s market cap is £2.06M.
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 168 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Feb 16, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 453,208,700 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in GB:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Physiomics PLC
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.